Ligand Pharmaceuticals (LGND) Non Operating Investment Income (2017 - 2026)

Ligand Pharmaceuticals has disclosed Non Operating Investment Income across 10 years of filings, most recently posting $3.9 million for Q1 2026.

• Non Operating Investment Income for Q1 2026 came in at $3.9 million, up 131.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.7 million (up 172.05% YoY), and the FY2025 annual result was $18.4 million, down 75.43% from the prior year.
• Non Operating Investment Income came in at $3.9 million for Q1 2026 at Ligand Pharmaceuticals, down from $22.1 million in the prior quarter.
• In the past five years, Non Operating Investment Income ranged from a high of $110.8 million in Q1 2024 to a low of -$23.9 million in Q4 2024.
• The 5-year median for Non Operating Investment Income is $2.4 million (2024), against an average of $10.1 million.
• Across the five-year window, Non Operating Investment Income jumped 430.27% in 2022 and plunged 1328.39% in 2023, its largest moves.
• Ligand Pharmaceuticals' Non Operating Investment Income stood at $44.2 million in 2022, then slumped by 63.78% to $16.0 million in 2023, then slumped by 249.14% to -$23.9 million in 2024, then surged by 192.32% to $22.1 million in 2025, then plunged by 82.46% to $3.9 million in 2026.
• The last three Non Operating Investment Income figures came in at $3.9 million (Q1 2026), $22.1 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.